NNVC - NanoViricides, Inc.
| Previous Close | 0.42 |
| Open | 0.43 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 0.36 - 0.43 |
| 52 Week Range | 0.36 - 1.64 |
| Volume | 217,183 |
| Avg. Volume | 133,244 |
| Market Cap | 24.835M |
| Beta | -0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.15 |
| Earnings Date | Feb 12, 2018 - Feb 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.30 |
- ACCESSWIRE•5 days ago
Wired News – AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress
LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on AbbVie Inc. (NYSE: ABBV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ABBV as the Company’s latest news hit the wire. On June 15, 2018, the Company announced that it has presented investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase-3 MURANO trial, assessing venetoclax in combination with rituximab (VenR) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) during the 23rd European Hematology Association (EHA) Annual Congress, Stockholm, held on June 16, 2018.
- PR Newswire•last month
NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates
SHELTON, Conn., May 22, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its third quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission yesterday. The Company reported that it had approximately $10.95 Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of 2.29M, as of March 31, 2018, the end of the reporting period. The Company's research and development (R&D) expenditure of approximately $1.03M in the current quarter was in line with our budgeted estimates.
- Associated Press•last month
NanoViricides: Fiscal 3Q Earnings Snapshot
The Shelton, Connecticut-based company said it had a loss of 3 cents per share. The company's shares closed at 53 cents. A year ago, they were trading at $1.29. _____ This story was generated by Automated ...
- PR Newswire•2 months ago
NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today
SHELTON, Conn., April 9, 2018 /PRNewswire/ -- NanoViricides, Inc. (the "Company") reports that its drug candidates in the HerpeCide™ program have been found to be safe based on multiple parameters in the recently completed initial non-GLP safety/toxicology study. No clinically observable adverse safety and toxicology effects were seen in this study of the Company's optimized topical dermal drug candidates. The drug candidates tested in this safety/toxicology study have previously shown broad-spectrum effectiveness against alphaherpesviruses, i.e.
- PR Newswire•3 months ago
NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin
SHELTON, Conn., March 19, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") has announced that it has expanded its in vivo testing agreement with the University of Wisconsin to encompass testing its topical anti-herpes agents in animal models of HSV-induced dermal, ocular and genital herpes virus infections. NanoViricides has previously reported excellent effectiveness of its earlier drug candidates in the HerpeCide™ program against the highly pathogenic, neurotropic strain of HSV-1, namely H129, leading to full survival of lethally infected mice. Since then, the Company has further improved these candidates. The resulting drug candidates have shown excellent efficacy in cell cultures against HSV-1, HSV-2, as well as VZV (aka the chickenpox virus, which is also the cause of shingles).
- Simply Wall St.•4 months ago
Is NanoViricides Inc’s (NYSEMKT:NNVC) CEO Paid Enough Relative To Peers?
Eugene Seymour took the helm as NanoViricides Inc’s (AMEX:NNVC) CEO and grew market cap to US$58.43M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial part ofRead More...
- ACCESSWIRE•4 months ago
Blog Exposure - Shire Gets BLA and Priority Review Status from FDA for Lanadelumab for the Prevention of HAE Attacks
Stock Monitor: NanoViricides Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 26, 2018 / Active-Investors.com has just released a free research report on Shire PLC (NASDAQ: SHPG ). If you want ...
- Associated Press•4 months ago
NanoViricides reports 2Q loss
On a per-share basis, the Shelton, Connecticut-based company said it had a loss of 4 cents. Losses, adjusted to extinguish debt, were 2 cents per share. The company's shares closed at 97 cents. A year ...
- PR Newswire•4 months ago
NanoViricides Files Quarterly Report for Period Ending December 31, 2017
SHELTON, Conn., Feb. 21, 2018 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its second quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission on Tuesday, February 20, 2018. The Company reported that it had approximately $12.0 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of December 31, 2017, the end of the reporting period. The Company's research and development (R&D) expenditure of approximately $1.4M in the current quarter was in line with our budgeted estimates.
- Simply Wall St.•4 months ago
How Does NanoViricides Inc (NYSEMKT:NNVC) Affect Your Portfolio Returns?
For NanoViricides Inc’s (AMEX:NNVC) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The beta measures NNVC’sRead More...
- Simply Wall St.•4 months ago
Who Are The Largest Shareholders In NanoViricides Inc (NYSEMKT:NNVC)?
In this article, I’m going to take a look at NanoViricides Inc’s (AMEX:NNVC) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
- PR Newswire•7 months ago
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
SHELTON, Conn. , Dec. 6, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that it has begun initial safety and toxicology evaluation of its optimized nanoviricides® ...
- Simply Wall St.•7 months ago
Is NanoViricides Inc (NNVC) A Financially Sound Company?
While small-cap stocks, such as NanoViricides Inc (AMEX:NNVC) with its market cap of USD $63.34M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
- PR Newswire•7 months ago
NanoViricides Files Quarterly Report for Period Ending September 30, 2017
SHELTON, Conn., Nov. 20, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its first quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission on Tuesday, November 14, 2017. NanoViricides reported that it had approximately $13.7 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of September 30, 2017, the end of the reporting period. The net cash used in operating activities during this quarter was approximately $1.56 M. The Company's research and development (R&D) expenditure have decreased for the quarter but are in line with our budgeted estimates.
- ACCESSWIRE•7 months ago
NanoViricides Signs Extension of Herpes Virus (HSV) Testing Agreement with University of Wisconsin
SHELTON, CT / ACCESSWIRE / November 8, 2017 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") has announced that it has extended and expanded its in vivo testing agreement with researchers ...
- PR Newswire•8 months ago
NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
SHELTON, Conn., Nov. 6, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") reports that Dr. Vivien Boniuk, Consultant in Ophthalmology at the Company, will present the successful results of certain anti-herpes nanoviricide treatments for Viral Acute Retinal Necrosis (v-ARN) at the 2017 Annual meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology to be held in New Orleans, LA. The same lead candidates that the Company has previously found to be highly effective against VZV in the shingles human skin patch model in Professor Moffat's Lab at SUNY Upstate Medical Center were evaluated for efficacy in this v-ARN mouse model study.
- PR Newswire•8 months ago
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center
The Company will conduct additional studies in order to finalize the candidates for clinical drug development, and to obtain IND-enabling pre-clinical data, under the extension. The final candidate is expected to undergo toxicology and safety studies leading to IND submission to the FDA for the treatment of shingles in humans.
- PR Newswire•8 months ago
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
SHELTON, Conn., Oct. 17, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") will present the results of its anti-herpes nanoviricide treatment for Viral Acute Retinal Necrosis (vARN) at the 2017 Annual meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology to be held in New Orleans, LA. The abstract of the study has been accepted for presentation at this OMIG meeting on November 10th, 2017. Dr. Vivien Boniuk, consultant in ophthalmology at NanoViricides, Inc. will make the scientific presentation. The presentation will cover both the inhibition of virus infection and prevention of ocular tissue damage following virus infection.
- PR Newswire•9 months ago
NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials
SHELTON, Conn., Sept. 29, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), reports that it has filed its financial year end annual report (Form 10-K) with the Securities and Exchange Commission (SEC) on Thursday, September 28, 2017 in a timely manner. NanoViricides, Inc. is a global leader in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enables direct attacks at multiple points on a virus particle.
- PR Newswire•9 months ago
NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017
SHELTON, Conn., Sept. 11, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE "NNVC") today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
- PR Newswire•11 months ago
NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin
SHELTON, Conn., July 10, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that its anti-shingles nanoviricides® drug candidates achieved dramatic reduction in infection of human skin by the varicella-zoster virus (VZV), the shingles virus. The antiviral effect of certain nanoviricide drug candidates was substantially greater than the effect of the standard positive control of cidofovir added into media.
- PR Newswire•last year
NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology
SHELTON, Conn., June 26, 2017 /PRNewswire/ -- NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its poster entitled "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" will be presented today at the 36th Annual Meeting of the American Society of Virology (ASV). Dr. Brian Friedrich, Senior Virologist of the Company, is presenting the Company's work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3) in this poster.
